BLK
BlackRock, Inc.
BLK has a slight edge over CARE overall, supported by stronger modeled upside and lower modeled downside.
CARE
Carter Bankshares, Inc.
CARE offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
CARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CARE's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CARE.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK's PE is in its expensive range at 28x.
CARE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.9x | $29.10 | — |
| Cheap | 6.8x | $39.97 | +37% |
| Fair | 12x | $69.41 | +139% |
| Forward | 12x | $29.10 | — |
| Expensive | 21x | $122 | +318% |
Historical ranges are pointers, not guarantees.
CARE has the edge over BLK in the historical PE scenario, which offers more potential upside but is not a forecast.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
CARE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect CARE's earnings and revenue to decline, with profitability weakening.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK earned $43.87 per share over the past year, up 11% from the year before.
CARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | -60% |
| Q3 2026 | $5.92 | +335% |
| Q2 2026 | $5.81 | +327% |
| Q1 2026 | $4.87 | +306% |
| Q4 2025 | $1.38 | +30% |
| Q3 2025 | $1.36 | +116% |
| Q2 2025 | $1.36 | +147% |
| Q1 2025 | $1.20 | +107% |
| Q4 2024 | $1.06 | +6% |
CARE has the edge over BLK on earnings, with more consistent year-over-year improvement.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BLK has the edge over CARE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK has the edge over CARE on profitability, with a higher operating margin.
CARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $46.2M | +18% |
| Q2 2026 | $68.7M | +84% |
| Q1 2026 | $106.9M | +189% |
| Q4 2025 | $39.8M | +15% |
| Q3 2025 | $39.1M | +14% |
| Q2 2025 | $37.3M | +11% |
| Q1 2025 | $37M | +11% |
| Q4 2024 | $34.5M | +13% |
CARE's revenue has grown year over year for 10 quarters in a row: $46M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -4.5 points |
| Q2 2026 | 54% | +26 points |
| Q1 2026 | 103% | +73 points |
| Q4 2025 | 28% | -3.1 points |
| Q3 2025 | 18% | -2.2 points |
| Q2 2025 | 29% | +11 points |
| Q1 2025 | 30% | +8.4 points |
| Q4 2024 | 31% | +37 points |
CARE's operating margin was 14% last quarter, down 4.5 points from the same quarter a year ago, near the bottom of its range since 2021.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BLK's free cash flow was $4.8B over the past year, up 22% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BLK.
CARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5K | -100% |
| Q2 2026 | -$262.9M | -3522% |
| Q1 2026 | $302.4M | +6131% |
| Q4 2025 | $9M | +8.2% |
| Q3 2025 | $10.3M | +22% |
| Q2 2025 | $7.7M | +$12M |
| Q1 2025 | $4.9M | -70% |
| Q4 2024 | $8.3M | +37% |
CARE's free cash flow was $48M over the past year, up 56% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CARE.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has 165M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
CARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -37.2K shares |
| 1 year | -2.2% | -493K shares |
| 3 years | -5% | -1.1M shares |
| 5 years | -17% | -4.5M shares |
CARE has the edge over BLK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2M |
| Q4 2025 | $6M |
| Q3 2025 | $4.9M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
CARE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
CARE has the edge over BLK on leverage, with a lower net debt burden relative to earnings.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
CARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 7.8 | Oversold |
CARE's weekly RSI is 48 (neutral) and its Stochastic is 8 (oversold).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
CARE PE vs Financial Services Sector
| Metric | CARE | Sector median | Relative |
|---|---|---|---|
| PE | 4.9x | 13x | 62% below |
| PE % | 0 | 63 | 63 pts below |
CARE has the edge over BLK on valuation relative to its sector.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK has the edge over CARE on trend strength, trading above more of its moving averages.
CARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.9 | 2.5% below |
| 20 week MA | $31.4 | 7.4% below |
| 50 week MA | $26.6 | 9.3% above |
| 100 week MA | $22.0 | 32% above |
| 200 week MA | $18.4 | 59% above |
CARE has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 59% above its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has finished higher in five of the last six years. It's up 12% so far in 2026.
CARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.3 | $10.8 | -54% |
| 2021 | $10.8 | $14.9 | +39% |
| 2022 | $14.9 | $16.7 | +12% |
| 2023 | $16.7 | $15.0 | -11% |
| 2024 | $15.0 | $17.6 | +18% |
| 2025 | $17.6 | $19.9 | +13% |
| 2026 YTD | $19.9 | $29.1 | +46% |
CARE has the edge over BLK on returns for 2026, with the stronger performance.